期刊文献+

三维适形放射治疗联合羟基喜树碱治疗局部晚期非小细胞肺癌疗效分析 被引量:2

Application of 3-dimensional conformal radiotherapy combined with hydroxycamptothecin in the treatment of local advanced NSCLC
原文传递
导出
摘要 目的评价三维适形放射治疗(3DCRT)联合羟基喜树碱(HCPT)治疗局部晚期非小细胞肺癌(NSCLC)的价值。方法95例患者随机分为治疗组和对照组,治疗组采用3DCRT加H CPT全身化疗,对照组单用3DCRT。结果治疗组和对照组近期疗效(CR+PR)分别为73.4%,62%(P<0.001)。1,2年生存率分别为65%,26%和54%,22%(P<0.01),差异具有统计学意义。结论3DCRT可以提高肿瘤局部剂量和局控率,H CPT使放疗增敏,二者结合,是有效治疗NSCLC的方法。 Objective To evaluate the value of 3-dimensional conformal radiotherapy combined with Hydroxycamptothecin(HCPT) in the treatment of local advanced non-small cell lung cancer. Methods A total of 95 cases were enrolled and randomly assigned to treatment group and control group. The treatment group was treated with 3-dimensional conformal radiotherapy(3DCRT) combined with I-ICPT. The control group was treated with 3DCRT only. Results Response rate (CR+PR) is respectively 73.4 % and 62 %. The response rate of treatment group is higher than that of control group(P 〈0.001). The one year, two year survival rates of these two groups were 65 %, 26 % and 54 %, 22 % respectively(P 〈0.01 ) the efficacy difference was significant. Conclusions 3DCRT can improve local dose of tumor and the local control rate. HCPT can increase radiosensibility, and it is an important treatment of NSCLC with 3DCRT combined HCPT.
出处 《肿瘤研究与临床》 CAS 2006年第1期30-31,共2页 Cancer Research and Clinic
关键词 三维适形放射治疗 羟基喜树碱 非小细胞肺癌 3-dimensional confomlal radiotherapy Hydroxyeamptothecin Non-small-cell lung cancer
  • 相关文献

参考文献6

二级参考文献13

  • 1[11]Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage Ⅲ non-small cell lung cancer:a randomized study[J].J Clin Oncol, 1996,14(4):1065 - 1070.
  • 2[12]Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer [J]. Semin Radiat Oncol, 1999,9(2 suppl1): 108 - 116.
  • 3[13]Belani CP.Aisner J,Day R,et al. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small lung cancer:three year follow-up[J]. Proc Annu Meet Am Soc Clin Oncol, 1997,16: A1608.
  • 4[1]Cox JD,Azarnia N,Byhardt RW,et al. A randomized phase Ⅰ/Ⅱ trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy:possible survival benefit with great than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage Ⅲ non-small cell lung carcinoma: report of Radiation Therapy Oncology Group 83 - 11[J].J Clin Oncol, 1990,8(9):1543 - 1555.
  • 5[2]Sause WT,Scott C,Taylor S,et al. Radiation Therapy Oncology Group (RTOG)88 - 08 and Eastern Cooperative Oncology Group (ECOG)4588:prelimitary results of a phase Ⅲ trial in regionally advanced unresectable non-small cell lung cancer[J].J Natl Cancer Inst, 1995,87(3):198 - 205.
  • 6[3]Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy(CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. CHART Steering Committee[J]. Lancet, 1997,350(9072):161 - 165.
  • 7[4]Saunders M,Rojas A,Lyn BE,et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less ) in non-small cell lung cancer[J]. Br J Cancer, 1998,78(10):1323 - 1328.
  • 8[5]King SC, Acker JC, Kussin PS, et al. High-dose hyperfractionated accelerated radiotherapy using a concurrent boost for the treatment of non-small cell lung cancer: unusual toxicity and promising early results[J].Int J Radiat Oncol Biol Phys, 1996,36(3):593-599.
  • 9[6]Rosenzweig KE, Mychalczak B,Fuks Z, et al. Final report of the 70.2 Gy and 75.6 Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer[J]. Cancer J,2000,6(2):82 - 87.
  • 10[7]Stokkel MP, Bakker PF, Heine R, et al. Staging of lymph nodes with FDG dual-headed PET in patients with non-small lung cancer[J].Nucl Med Commun,1999,20(11):1001 - 1007.

共引文献67

同被引文献60

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部